Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

FY2019 EPS Estimates for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Decreased by Oppenheimer

researchsnappy by researchsnappy
November 28, 2019
in Investment Research
0
FY2019 EPS Estimates for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Decreased by Oppenheimer
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Madrigal Pharmaceuticals logo

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) – Stock analysts at Oppenheimer lowered their FY2019 EPS estimates for shares of Madrigal Pharmaceuticals in a report issued on Wednesday, November 6th, according to Zacks Investment Research. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of ($5.39) for the year, down from their prior estimate of ($4.86). Oppenheimer also issued estimates for Madrigal Pharmaceuticals’ Q4 2019 earnings at ($1.74) EPS, FY2020 earnings at ($6.46) EPS, FY2021 earnings at ($7.55) EPS, FY2022 earnings at ($3.43) EPS and FY2023 earnings at $2.61 EPS.

Several other research firms also recently weighed in on MDGL. Cowen restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, November 12th. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 9th. HC Wainwright lowered their target price on Madrigal Pharmaceuticals from $225.00 to $215.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. ValuEngine upgraded Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, BidaskClub upgraded Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $161.13.

MDGL stock opened at $110.41 on Monday. Madrigal Pharmaceuticals has a 1-year low of $82.31 and a 1-year high of $148.18. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -49.73 and a beta of 1.11. The business has a 50 day simple moving average of $95.47 and a two-hundred day simple moving average of $95.44.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.42) by $0.03. During the same period in the prior year, the company earned ($0.56) earnings per share.

Several hedge funds and other institutional investors have recently bought and sold shares of MDGL. Tower Research Capital LLC TRC purchased a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $41,000. Captrust Financial Advisors purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at $163,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at $215,000. Stanley Laman Group Ltd. purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at $256,000. Finally, Jane Street Group LLC raised its holdings in Madrigal Pharmaceuticals by 7.8% during the 2nd quarter. Jane Street Group LLC now owns 2,523 shares of the biopharmaceutical company’s stock valued at $265,000 after buying an additional 183 shares during the period. Hedge funds and other institutional investors own 62.15% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Recommended Story: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Madrigal Pharmaceuticals (NASDAQ:MDGL)



Receive News & Ratings for Madrigal Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Lithium-ion Batteries for Consumer Electronics Market Research Study including Growth Factors, Market Key Players, Types, Application And New Developments Analysis (2019 – 2026)

Next Post

Detecting and quantifying causal associations in large nonlinear time series datasets

Next Post
Evolutionarily conserved regulation of sleep by epidermal growth factor receptor signaling

Detecting and quantifying causal associations in large nonlinear time series datasets

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News
  • Top Company News

Top 10 Market Research Companies in the world

3 Best Market Research Certifications in High Demand

The Latest Market Research Trends Shaping 2024

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2024 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2024 researchsnappy.com